$0.23
6.25%
Nasdaq, Apr 21, 08:10 pm CET
ISIN
US3724461047
Symbol
GNPX
Sector
Industry

Genprex, Inc. Stock price

$0.24
-0.16 40.00% 1M
-0.10 29.39% 6M
-0.61 71.82% YTD
-1.97 89.14% 1Y
-72.96 99.67% 3Y
-83.36 99.71% 5Y
-187.76 99.87% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.02 6.07%
ISIN
US3724461047
Symbol
GNPX
Sector
Industry

Key metrics

Market capitalization $5.80m
Enterprise Value $4.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.61
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.17m
Free Cash Flow (TTM) Free Cash Flow $-17.15m
Cash position $1.60m
EPS (TTM) EPS $-8.35
P/E forward negative
Short interest 1.15%
Show more

Is Genprex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Genprex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Genprex, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Genprex, Inc.:

Buy
100%

Financial data from Genprex, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
50% 50%
-
-0.01 -0.01
50% 50%
-
- Selling and Administrative Expenses 11 11
21% 21%
-
- Research and Development Expense 11 11
40% 40%
-
-21 -21
32% 32%
-
- Depreciation and Amortization 0.01 0.01
50% 50%
-
EBIT (Operating Income) EBIT -21 -21
32% 32%
-
Net Profit -21 -21
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genprex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genprex, Inc. Stock News

Neutral
PRNewsWire
26 days ago
Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas , March 26, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present a...
Neutral
PRNewsWire
27 days ago
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes AUSTIN, Texas , March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 ...
Neutral
PRNewsWire
about 2 months ago
AUSTIN, Texas , March 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy....
More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office United States
CEO Ryan Confer
Employees 15
Founded 2009
Website www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today